Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Free Cash Flow: 2023-2025

Historic Free Cash Flow for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to -$29.7 million.

  • Tonix Pharmaceuticals Holding's Free Cash Flow fell 58.13% to -$29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$76.3 million, marking a year-over-year decrease of 10.31%. This contributed to the annual value of -$61.0 million for FY2024, which is 44.45% up from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Free Cash Flow stood at -$29.7 million for Q3 2025, which was down 93.65% from -$15.4 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Free Cash Flow's 5-year high stood at -$9.9 million during Q2 2024, with a 5-year trough of -$36.7 million in Q1 2023.
  • In the last 3 years, Tonix Pharmaceuticals Holding's Free Cash Flow had a median value of -$18.8 million in 2024 and averaged -$21.1 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first spiked by 60.66% in 2024, then plummeted by 58.13% in 2025.
  • Tonix Pharmaceuticals Holding's Free Cash Flow (Quarterly) stood at -$22.8 million in 2023, then skyrocketed by 35.76% to -$14.6 million in 2024, then crashed by 58.13% to -$29.7 million in 2025.
  • Its Free Cash Flow was -$29.7 million in Q3 2025, compared to -$15.4 million in Q2 2025 and -$16.6 million in Q1 2025.